Nuvalent, Inc. (NUVL)

NMS – Цена в реальном времени. Валюта: USD

123.52

-0.01 (-0.01%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

123.75

+0.23 (0.19%)

После закрытия: Jun 26, 2026, 6:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Nuvalent, Inc. (NUVL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nuvalent, Inc. (NUVL)

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Видео

No Data

Пресс-релизы

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Nuvalent, Inc. (NASDAQ: NUVL)

Search stocks

Nuvalent, Inc. (NUVL)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Nuvalent, Inc. (NUVL)

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout

Видео

No Data

Пресс-релизы

NUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Shareholder Alert: Ademi LLP investigates whether Nuvalent, Inc. is obtaining a Fair Price for Public Shareholders

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Nuvalent, Inc. (NASDAQ: NUVL)